The Column Group is a venture capital firm that focuses on building early-stage drug discovery companies based on unique scientific platforms and potential breakthrough therapeutics. Their strategy emphasizes long-term value generation by building fundamentally strong, science-driven companies from the ground up, primarily in the life sciences, including pharmaceuticals, biotechnology, and bioinformatics.
95% of their portfolio is in Biotech & Life Sciences. Deal activity increased 50% year-over-year (3 deals in the last 12 months). Average disclosed round size is $106.9M (across 20 rounds with reported amounts).
Portfolio
20
Fund Size
$4.2B
Top Stage
Series B
Last 12 Mo
3
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
20 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Atavistik Bio | Series B | $120M | Dec 2025 |
 Tr1X, Inc. | Unknown | $50M | Oct 2025 |
 Nilo Therapeutics | Series A | $101M | Oct 2025 |
 Surrozen, Inc. | Series D | $175M | Mar 2025 |
| RRAPT Therapeutics, Inc. | Series D | $150M | Dec 2024 |
| Tr1X, Inc. | Series A | $75M | Jan 2024 |
 Remix Therapeutics | Series C | $60M | Jan 2024 |
| KKimia Therapeutics, Inc. | Series A | $55M | Dec 2023 |
 Carmot Therapeutics | Series E | $150M | May 2023 |
| CCajal Neuroscience | Series A | $96M | Nov 2022 |
 Plexium, Inc. | Growth | $102M | Feb 2022 |
 Eikon Therapeutics | Series B | $517.8M | Jan 2022 |
| Plexium, Inc. | Series A | $35M | Jan 2021 |
| Remix Therapeutics | Series A | $81M | Dec 2020 |
 A2 Biotherapeutics | Series B | $71.5M | Oct 2020 |
 Tenaya Therapeutics, Inc. | Series B | $92M | Oct 2019 |
 Arcus Biosciences, Inc. | Series B | $70M | Sep 2016 |
 eFFECTOR Therapeutics | Series B | $40M | Dec 2015 |
 Kallyope Inc. | Series A | $44M | Dec 2015 |
| OORIC Pharmaceuticals | Series B | $53M | Dec 2015 |
Top Co-Investors
Alexandria Venture Investments7 shared
Lux Capital7 shared
Foresite Capital5 shared
Casdin Capital3 shared
RA Capital Management3 shared
DCVC3 shared
GV (Google Ventures)2 shared
Atlas Venture2 shared
ARCH Venture Partners2 shared
Nextech Invest2 shared
Samsara BioCapital2 shared
UC Investments2 shared
Horizon Ventures2 shared
Deep Track Capital2 shared
OrbiMed2 shared
Willett Advisors2 shared
Surveyor Capital2 shared
Pivotal bioVenture Partners2 shared
Novartis Venture Fund2 shared
Last updated: 12 April 2026